KSL Biomedical specializes in a range of advanced technologies focused on translational medicine, particularly in the fields of immunology, oncology, and genomics. The company offers a comprehensive suite of services, including regulatory and quality consulting, clinical trial support, and contract research organization (CRO) services. Their proprietary in vitro diagnostics (IVD) and personalized medicine applications are complemented by novel biomarker development and targeted clinical laboratory diagnostics. KSL's capabilities extend to the design, validation, and manufacturing of bioassays, as well as the development of laboratory-developed tests (LDTs) and international intellectual property strategies for technology companies based in the USA and China.

In addition to their diagnostic services, KSL Biomedical has established integrated clinical laboratories that facilitate clinical studies and sample biobanking for various diagnostic markers. Their clinical research experts guide the collection of clinical evidence and develop strategies for medical device, IVD, and pharmaceutical companies. KSL's laboratories are accredited by CLIA, NYSDOH, and CAP, ensuring compliance and quality in their testing services. They also provide a fast track to regulatory approval and commercialization for novel diagnostics, exemplified by their development of the Laminin 332 test, which demonstrates high sensitivity and specificity for identifying specific patient populations.

United States

Proprietary applications in diagnostics and therapeutics.
International technology development. Translational medicine impacting Immunology, Oncology and Genomics.

KSL Biomedical

Company Details